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This data article contains complementary ﬁgures and results related
to the research article entitled “Negative Fgf8-Bmp2 feed-back is
controlled by miR-130 during early cardiac speciﬁcation” [15],
which reveals what speciﬁc role miR-130 plays during the cardiac
induction process. This study evidenced miR-130 a putative
microRNA that targets Erk1/2 (Mapk1) 30UTR- as a necessary
linkage in the control of Fgf8 signaling, mediated by Bmp2. Thus,
miR-130 regulates a negative Fgf8-Bmp2 feed-back loop responsible
to achieve early cardiac speciﬁcation. A signiﬁcant aspect support-
ing our conclusions is given by the expression pattern of miR-130
during early cardiac speciﬁcation, as well as by those results
obtained after the designed experimental procedures. The data
presented here reveal that miR-133 is also expressed within the
precardiac areas during early cardiogenesis, pattern which is
comparable to that of FGFR1, receptor involved in the Fgf8/ERK
signaling pathway. Interestingly, our miR-133 overexpression
experiments resulted in a decrease of Fgf8 expression, whereas
we observed an increase of Bmp2 and subsequently of cardiac
speciﬁc markers Nkx-2.5 and Gata4. Additionally, our loss-of-
function experiments -through Fgf8 siRNA electroporation- showed
an increase of miR-133 expression. Finally, after our Bmp2
experiments, we observed that miR-133 is upstream-regulated byvier Inc. This is an open access article under the CC BY license
/j.ydbio.2015.07.007
C. Lopez-Sanchez et al. / Data in Brief 5 (2015) 59–6460Bmp2. All those results suggest that miR-133 also constitutes a
crucial linkage in the crosstalk between Fgf8 and Bmp2 signaling by
regulating the Fgf8/ERK pathway during cardiac induction.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableSubject area BiologyMore speciﬁc subject
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 miR-133 exerts a regulatory role in Fgf8–Bmp2 signaling during early cardiac speciﬁcation.1. Data
Fgf8 constitutes a crucial factor involved in MAPK/ERK signaling pathway [8]. Also, FGF receptors
have demonstrated to play a signiﬁcant role during the early steps in the Fgf8/ERK signaling cascade
[6,9]. Although there is no evidence about the role of FGF receptors during early cardiogenesis, there
are previous studies where FGFR1 has been identiﬁed in the endoderm underlying the precardiac
mesoderm [16,17]. However, its functional role has been preferentially involved in cell proliferation
rather than in cell differentiation [19]. It has been reported that cardiomyocyte proliferation is
suppressed after miR-133 overexpression [13], and that miR-133 is also involved in late stages of
mouse cardiac development as well as in molecular mechanisms regulating adult cardiovascular
diseases [1,2,7,12,18].
To further analyze what mechanism regulates these signaling pathways, we will explore herein
miR-133 expression and function. Although previous studies have provided data about miR-133
expression in chick embryo [5], it has only been analyzed in late stages of cardiac development. Thus,
we have analyzed miR-133 expression from the primitive streak stages to the primitive cardiac tube
formation (Fig. 1), expression which is already detectable at gastrula stages throughout the entire
primitive streak, including the precardiac cells. Subsequently, its expression spreads laterally and
concentrates into the ﬁrst cardiac ﬁeld (FCF) and the underlying endoderm, to ﬁnally express
restrictively at the splachnic mesoderm of the primitive endocardial tube. This topographical location
of miR-133 shows a similar distribution to that of Fgfr1 [16,17]. Since FGFR1 has been proposed as a
crucial factor involved in Fgf8/ERK signaling pathway in different experimental models [8,11], it is
reasonable to consider a close relationship between miR-133 and Fgfr1 during cardiogenesis.
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Fig. 1. Whole-mount ISH analyses for miR-133 during early chick development. Note the expression from the primitive streak
(ps), through FCF, to the primitive endocardial tube level (pet). The white lines indicate the transverse section level, showing
miR-133 expression in the precardiac mesoderm (arrow) and the underlying endoderm (arrowhead). Hensen's node: Hn.
Neural plate: np.
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we analyzed the effects of miR-133 overexpression on the precardiac primitive streak cells, resulting
in Fgf8 inhibition and Bmp2 increase. Subsequently, Nkx-2.5 and Gata4 increase as well (Fig. 2).C
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Fig. 2. Effect of miR-133 gain-of-function on primitive endocardial tube speciﬁcation. Embryos electroporated at the level of the
primitive streak precardiac (left image) at stage PS4: Whole-mount ISH for Fgf8, Bmp2, Nkx-2.5 and Gata4. Note the dramatic
reduced Fgf8 expression (arrowheads), whereas Bmp2, Nkx-2.5 and Gata4 are signiﬁcantly increased (arrows), at the primitive
endocardial tube level. Visualization of CFDA expression of embryos processed for ISH is shown in the immediate upper panel.
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Fig. 3. Effect of Fgf8 loss-of-function on primitive endocardial tube speciﬁcation. Whole-mount ISH for miR-133. Embryos
electroporated at the level of the primitive streak precardiac cells (left image), either with the control construct or Fgf8 siRNA
expressing construct. Note that at the primitive endocardial tube level miR-133 is markedly increased (arrow). EGFP expression
of experimental embryos is shown in the immediate left panel.
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increased miR-133 expression (Fig. 3). It is also noteworthy that our Bmp2 overexpression
experiments induced miR-133 expression, whereas noggin soaked beads administration -speciﬁcally
into FCF, showed a decrease of miR-133 expression in the ipsilateral endocardial tube (Fig. 4),
suggesting that miR-133 is upstream-regulated by Bmp2. All the above results clearly indicate that a
reciprocal repression between miR-133 and Fgf8 regulates cardiac induction through Bmp2 signaling
(Fig. 5), thus constituting complementary data to those obtained after our miR-130 analysis [15].
However, although miR-133 may be identiﬁed as a putative microRNA that targets FGFR1 30UTR -site
broadly conserved among vertebrates, its connection for Fgf8/ERK pathway in this process remains to
be further established.2. Experimental design, materials and methods
Fertilized eggs (Granja Santa Isabel, Córdoba, Spain) were incubated at 38 1C in forced-draft
humidiﬁed incubators. Embryos were staged (PS stages: [14]; HH stages: [10]) and subjected to early
chick (EC) embryo culture [3]. Two groups of embryos were selected for experiments:
2.1. Group 1. Embryo electroporation of precardiac primitive streak cells
Cultured embryos were injected and electroporated in precardiac primitive streak cells. For gain-
of-function experiments, two different groups of embryos were electroporated with Bmp2 expressing
construct (pIRES-Bmp2-EGFP) and pre-miR-133, respectively. For loss-of-function experiments, a
group of embryos was electroporated with Fgf8 siRNA expressing construct (pSilencer-Fgf8). For
control embryos, EGFP expressing construct (pCAGGs-EGFP), or CFDA, was electroporated. Embryos
were additionally incubated for 14 to 16 h.
2.2. Group 2. Bead implantation
For loss-of-function experiments, beads were soaked in noggin (an antagonist of BMP signals)
solution and implanted at the desired site. The embryos were additionally incubated for 6–8 h.
After the experimental procedures, the selected embryos were ﬁxed overnight in 4% PFA,
dehydrated in methanol and stored at 20 1C. Subsequently, they were processed for whole mount
in situ hybridization: embryos were hydrated by incubation in graded methanol/PBT steps to a pure
sterile PBT solution and processed for ISH following standard procedure [4] using antisense-Nkx2.5,
-Bmp2, -Fgf8, and -Gata4 labeled probes, respectively. A group of embryos was processed [5] for ISH
with LNA-labelled microRNA probes (Exiqon) against miR-133.
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Fig. 4. Effect of Bmp2 gain- and loss-of-function on primitive endocardial tube speciﬁcation: whole-mount ISH for miR-133 .
(A) Embryo electroporated at the level of the primitive streak precardiac at stage PS4 (left image), either with the control
construct or with Bmp2 expressing construct. Note the signiﬁcant increase of miR-133 expression (arrow) at the primitive
endocardial tube level. Visualization of EGFP expression of embryos processed for ISH is shown in the immediate left panel.
(B) After noggin soaked bead application just inside FCF, at PS11 stage (right drawing), miR-133 is diminished at the level of the
ipsilateral endocardial tube (arrowhead).
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Fig. 5. Proposed model for early cardiac speciﬁcation. Our model indicates that the earliest cardiac markers -Nkx-2.5 and Gata4-
are induced by Bmp2, which is repressed by Fgf8. Moreover, Bmp2 induces miR-130 and miR-133. Both repress Erk1/2 and
FGFR1, respectively. Since Fgf8 is controlled by these two factors -Erk1/2 and FGFR1, Bmp2 modulates Fgf8 expression. Thus,
miR-130 and miR-133 act as necessary linkages in the control of Fgf8 signaling, mediated by Bmp2, establishing a negative feed-
back loop responsible to achieve the initial cardiac speciﬁcation.
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